Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BM-MSC-derived sEVs for Retinitis Pigmentosa
NCT06242379Phase 2Recruiting
- Sponsor
- Mahidol University
- Start
- May 2024
- Primary completion
- Dec 2026
- Modality
- Lipid-based Nanoparticles, Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of bone marrow mesenchymal stem cell derived extracellular vesicles in retinitis pigmentosa (RP), sponsored by Mahidol University. Started May 2024; status: recruiting.
02
Drugs
bone marrow mesenchymal stem cell derived extracellular vesicles
03
Conditions
retinitis pigmentosa (RP)
Beyond the preview
Go deeper on NCT06242379.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06242379.